AIM ImmunoTech Inc (AIM)

Form 8-K - Current report

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules

OCALA, Fla., June 09, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the...

Form S-1 - General form for registration of securities under the Securities Act of 1933

AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

OCALA, Fla., June 08, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the...

Form 8-K - Current report

AIM ImmunoTech Releases Virtual Investor ‘What This Means’ Video Segment Discussing Ampligen’s Potential in Ebola Virus Disease Preparedness

Video segment examines current Ebola outbreak concerns, unmet need surrounding the Bundibugyo strain and...

AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones

OCALA, Fla., June 01, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

AIM ImmunoTech Announces Emerging Ebola Opportunity for Ampligen Amid Escalating Global Health Concerns and WHO Emergency Declaration

Previously published Biosafety Level 4 pre-clinical study showed 100% survival with early treatment following...

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement

OCALA, Fla., May 20, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the...

Form 424B5 - Prospectus [Rule 424(b)(5)]